RET and cancer: The existence of targetable oncogenic mutations was excluded by utilizing the Illumina amplicon cancer panel (TSACP), sequencing 212 regions in 48 cancer-related genes including EGFR, BRAF, KRAS, MET, and RET (Fig. 2d).